白葡奈氏菌片联合布地格福吸入气雾剂治疗COPD合并哮喘疗效观察

目的探讨白葡奈氏菌片联合布地格福吸入气雾剂治疗慢性阻塞性肺疾病(COPD)合并哮喘的疗效和肺功能的影响。方法回顾性分析2020年1月至2022年6月COPD合并哮喘患者60例,根据是否联合白葡奈氏菌片治疗分为对照组和观察组,两组患者予布地格福吸入气雾剂治疗,观察组联合白葡奈氏菌片治疗。比较治疗后生活质量评分、运动耐力、哮喘症状控制评估及急性发作情况,统计治疗前后肺功能的改善程度及炎症指标变化。结果经治疗后,两组患者生活质量评分、运动耐力、哮喘症状控制评分、肺功能和炎症指标均有改善,观察组改善程度明显优于对照组(P<0.05)。1年治疗期间,观察组患者急性发作次数和急性加重发作次数低于对照组(P<0.05)。结论白葡奈氏菌片联合布地格福吸入气雾剂治疗COPD合并哮喘,能有效提高临床疗效,并显著改善肺功能和提高生活质量。

Objective To explore the clinical efficacy of staphylococcus and neisseria tablets combined with budegfort inhalation aerosol in the treatment of chronic obstructive pulmonary disease(COPD)complicated with asthma and its influence on lung function.Methods Sixty COPD patients with asthma admitted to our hospital from January 2020 to June 2022 were retrospectively analyzed.They were divided into the control group and the observation group according to whether they were treated with staphylococcus and neisseria tablets.Both groups were treated with budegfort inhalation aerosol,while the observation group was treated with staphylococcus and neisseria tablets.The quality of life score,exercise endurance,asthma control test and acute attack were compared between the two groups after treatment,and the improvement degree of lung function and the changes of inflammatory indexes before and after treatment were counted.Results After treatment,the quality of life score,exercise endurance,asthma symptom control score,lung function and inflammation index of the two groups were all improved,and the improvement degree of the observation group was obviously better than that of the control group(P<0.05).During the one-year treatment,the number of acute attacks and acute exacerbations in the observation group was significantly lower than that in the control group(P<0.05).Conclusion The treatment of COPD complicated with asthma with staphylococcus and neisseria tablets combined with budegfort inhalation aerosol can effectively improve the clinical efficacy,and significantly improve the lung function and life quality of patients.